How do 12-month visual outcomes and injection loads compare between ranibizumab and aflibercept for neovascular age-related macular degeneration in a treat-and-extend regimen?

Findings  In this randomized clinical trial, a 12-month interim analysis of data from 278 participants found a mean best-corrected visual acuity letter score change from baseline to month 12 of 7.2 for ranibizumab and 4.9 for aflibercept. The mean number of injections was 9.7 in both arms.

Meaning  Neither aflibercept nor ranibizumab were superior to the other regarding 12-month average visual acuity gains and injection numbers using a treat-and-extend regimen.